Astrotech Corp Stock Price, News & Analysis

Astrotech Corporation (Nasdaq: ASTC) reported a pivotal fiscal year 2021, raising $74.3 million in gross proceeds through equity offerings, strengthening its balance sheet. The company aims to enhance sales of its mass spectrometry instruments and engage in strategic growth opportunities. Its TRACER 1000™, the first certified mass spectrometry-based explosives trace detector, secured its initial order for international airport deployment. Revenue reached $334,000 in FY2021, alongside reduced operational costs by approximately $2.1 million after optimizing its real estate footprint.

Astrotech Corporation (NASDAQ: ASTC) announced a significant purchase order for its TRACER 1000 explosives trace detector, marking its first deployment at airport security checkpoints. The TRACER 1000, already used at cargo facilities, will now operate in 15 locations across 10 countries in Europe and Asia. This mass spectrometry-based technology offers advantages such as high sensitivity, low false alarms, and has received ECAC certification. CEO Thomas B. Pickens reported increased interest in the TRACER 1000 as air travel recovers post-COVID, potentially improving operational efficiency at airports.

Astrotech Corporation (NASDAQ: ASTC) has appointed Joe Levinthal as Chief Science Officer of its AgLAB Inc. subsidiary. Levinthal, a veteran in the hemp and cannabis industry, will lead the product development team. His expertise lies in mass spectrometry and scientific instrumentation applied to hemp and cannabis products. The company is focused on enhancing its AgLAB-1000-D2 technology, which optimizes distillation processes, promising higher yields and improved real-time information for processors. This strategic hire is expected to strengthen AgLAB’s innovative capacities and product offerings.

Astrotech Corporation (NASDAQ: ASTC) has reported its third-quarter fiscal year 2021 financial results, highlighting a $50.1 million raise to enhance growth. The funds will support expected sales increases for products like the TRACER 1000™ and AgLAB-1000-D2™. Additionally, Astrotech has partnered with Sanmina Corporation for manufacturing and initiated a study with Cleveland Clinic for its BreathTest-1000™. Operating expenses have decreased by 22.3% year-over-year, while projected monthly cash outlay is around $500,000.

Astrotech Corporation (NASDAQ: ASTC) has successfully completed its public offering of 24,885,828 shares of common stock at $1.50 per share, yielding gross proceeds of approximately $37.3 million. This offering included 3,245,977 shares sold through the underwriter's option. Proceeds will be allocated for general corporate purposes, working capital, and capital expenditures. The offering was conducted under a 'shelf' registration statement effective since March 15, 2021, with H.C. Wainwright & Co. as the sole book-running manager.

Astrotech Corporation (NASDAQ: ASTC) announced an increase in its public offering to 21,639,851 shares at $1.50 each, expecting gross proceeds of about $32.5 million. The offering, managed by H.C. Wainwright & Co., is set to close around April 12, 2021, pending customary conditions. An additional 3,245,977 shares may be purchased by the underwriter within 30 days. The net proceeds will be utilized for general corporate purposes, including working capital and capital expenditures.

Astrotech Corporation (NASDAQ: ASTC) has entered an underwriting agreement with H.C. Wainwright & Co. for the firm purchase of 6,666,667 shares of common stock at $1.50 per share, aiming for approximately $10 million in gross proceeds. The offering is set to close around April 12, 2021, pending customary conditions. An additional 1,000,000 shares may be sold under a 30-day option. The funds will be used for general corporate purposes and capital expenditures. The offering is part of a shelf registration statement effective March 15, 2021.

Astrotech Corporation's subsidiary, BreathTech, has signed an Investigator-Initiated Study Agreement with Cleveland Clinic to use its BreathTest-1000™ for analyzing COVID-19 diagnosis via exhaled breath. The pilot study will compare breath samples between positive and negative COVID-19 PCR test subjects to evaluate volatile organic compounds (VOCs). Successful results may lead to FDA emergency use authorization for commercial use. The study is significant as it aims for early illness detection, with Cleveland Clinic's past research supporting VOC metabolite technology.

Astrotech Corporation (NASDAQ: ASTC) has announced a manufacturing agreement with Sanmina Corporation for its mass spectrometry products. After a thorough evaluation of contract manufacturing organizations, Astrotech's CEO expressed confidence in Sanmina's capabilities to support the company's growth plans. The agreement includes the production of 1st Detect's TRACER 1000™ and future manufacturing of AgLAB's AgLAB-1000™ and BreathTech's BreathTest-1000™ products.